SpectraLine 823

The 823 nm Configuration

The SpectraLine 823 operates at 823 nm — a specific near-infrared wavelength that appears in published photobiomodulation research. Unlike the more widely adopted 810 nm or 830 nm configurations, 823 nm has been identified in several peer-reviewed investigations as a wavelength of interest, particularly in transcranial PBM contexts.

The SpectraLine 823 is not a consumer wellness device. It is designed for clinics, practitioners, and researchers who understand the distinction between device parameter specification and published research findings — and who require documentation, reproducibility, and a manufacturing chain with traceable quality processes.

Engineering Specification

The helmet form factor provides consistent cranial coverage, with LED placement and optics designed to deliver measured irradiance across the treatment area. Each unit is specified to 823 nm with tight wavelength tolerance, and irradiance output is measured and documented at the time of manufacturing.

Our approach: every parameter is defined before a device is specified. Wavelength, irradiance (mW/cm²), dose delivery (J/cm²), and operating thermal limits are set by specification, not estimated. ISO-certified manufacturing partners build to these requirements.

Research Context

The following independent studies involve the 823 nm wavelength or closely related transcranial PBM research. These studies were conducted entirely independently of Zubrio Devices. We reference them solely to contextualize the wavelength — we make no claim that the SpectraLine 823 treats, cures, or prevents any disease or condition described in these or any other studies.

• Cassano et al. (2016) — Review of Transcranial Photobiomodulation for Major Depressive Disorder. Published in Neuropsychiatric Disease and Treatment, this review discusses the 810–830 nm range as wavelengths examined in published research protocols. The 823 nm wavelength appears in this body of independent literature.

• Hamblin, M.R. (2016) — Shining Light on the Head: Photobiomodulation for Brain Disorders. BBA Clinical. Examines wavelengths in the 800–830 nm range in animal models and early-stage human investigations.

• Hamblin, M.R. (2017) — Mechanisms and Applications of the Anti-inflammatory Effects of Photobiomodulation. AIMS Biophysics. Widely cited foundational PBM mechanisms review.

The SpectraLine 823 is a general wellness device. The research above is cited for informational and educational purposes only, consistent with our commitment to transparency about the science and its limitations.

Availability

The SpectraLine 823 is available on a limited early-access basis. Allocations are prioritized for clinics and practitioners with documented use cases. No online ordering. All inquiries reviewed directly.